Interview With Sven Van Den Berghe CEO of Pantera
Welcome to the Founder Spotlight series, another episode with Sven Van den Berghe, CEO of PanTera. The global shortage of actinium-225 (Ac-225) is a significant challenge for developing targeted cancer therapies. Currently, the global supply of Ac-225 is estimated at only 3 Curies per year, which is inadequate for the increasing number of clinical trials … Continued